Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer

Clinical Trial ID NCT00920192

Rank	Title	Journal	Year	PubWeight™‹?›
1	HCC and angiogenesis: possible targets and future directions.	Nat Rev Clin Oncol	2011	2.10
2	MET: a promising anticancer therapeutic target.	Nat Rev Clin Oncol	2012	1.71
3	Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.	Oncotarget	2012	1.55
4	Targeting the HGF/Met signaling pathway in cancer therapy.	Expert Opin Ther Targets	2012	1.45
5	EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.	Curr Mol Pharmacol	2010	1.29
6	Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.	Int J Hepatol	2013	0.99
7	MET inhibitors for treatment of advanced hepatocellular carcinoma: A review.	World J Gastroenterol	2015	0.84
8	Targeted therapies in the treatment of advanced hepatocellular carcinoma.	Clin Med Insights Oncol	2013	0.83
9	Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma.	BMC Cancer	2010	0.79
10	Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.	J Clin Pharmacol	2015	0.75